GLP-1 Drugs Before Surgery: What the Aspiration-Risk Evidence Shows

Delayed gastric emptying is not a rare side effect of GLP-1 drugs — it's part of how they work, part of why food feels more filling and why nausea is the most common complaint. Under general anesthesia, that same mechanism raises a specific, mechanical concern: a stomach that hasn't fully emptied on the schedule standard fasting guidelines assume is a stomach that can still hold enough content to be aspirated if it comes back up during intubation.

The study that actually measured it

Concern based on mechanism is one thing; concern based on a direct measurement is another. A 2024 study in *JAMA Surgery* used gastric ultrasonography — a bedside imaging technique that can directly assess how much content is sitting in the stomach — on 124 patients who had followed standard preprocedural fasting guidelines before an elective procedure¹. Among patients taking a once-weekly GLP-1 receptor agonist, 56% showed increased residual gastric content on ultrasound, compared with 19% of patients not taking one. After adjusting for confounding factors, GLP-1 use was associated with a 2.48-times higher prevalence of increased residual gastric content. That's not a theoretical risk based on how the drug is supposed to work — it's a direct measurement showing that standard fasting time was, for a meaningful share of these patients, not enough.

Duration of treatment mattered less than expected

One counterintuitive finding from the same study: how long a patient had paused their GLP-1 drug before the procedure was not associated with the prevalence of increased gastric content in this sample. That complicates the simple assumption that "stop it for X days and you're in the clear" — the effect on gastric emptying doesn't appear to wash out on a predictable timeline the way blood levels of the drug do.

What the anesthesia literature currently recommends

A 2024 review in the *British Journal of Anaesthesia*, written specifically to give perioperative clinicians evidence-based guidance, reaches a duration-dependent conclusion: GLP-1 receptor agonists delay gastric emptying, but ongoing treatment attenuates that effect over time, and after more than 12 weeks of treatment, standard fasting times likely suffice for most otherwise low-risk patients². The same review specifically advises added caution in patients who have recently started a GLP-1 drug, where the delay is most pronounced and least predictable. This is a professional synthesis of the current evidence, not a universal protocol — guidance in this area is still evolving, and individual institutions and anesthesia teams set their own specific pre-procedure instructions.

What this means for you, practically

There is no single "stop N days before surgery" number backed by strong enough evidence for the Desk to print one here, and neither of the sources above offers one either — that's the honest state of the evidence, not an omission. What both papers agree matters: tell your surgical and anesthesia team you are taking a GLP-1 drug, how long you've been on it, and when your last dose was, well before the day of the procedure — not as a formality, but because it changes their real-time risk assessment and may change their fasting or airway-management approach. This applies whether you're on a brand-name product or a compounded formulation from a telehealth provider; see is compounded GLP-1 legit and safe if a provider's paperwork doesn't already make that easy to document. It's also worth knowing how long the drug itself is actually in your system going into that conversation — see how long GLP-1 drugs stay in your system for the half-life numbers behind that question. The broader GI side-effect picture, including the FDA's ileus warning added to Wegovy's label in 2023, is covered in GLP-1 side effects, and the rest of the Desk's sourced evidence is in the research library.